Zobrazeno 1 - 10
of 1 434
pro vyhledávání: '"upadacitinib"'
Autor:
Junlan Liao, Ziyu Wang, Jianyong Zhang, Haibo Tan, Zhihao Zhang, Shan Zhang, Shasha Hu, Hongling Geng, Zhiying Zhan, Jiaxin Wei, Zhiling Li, Ertao Jia
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-9 (2024)
Abstract Background Patients with psoriatic arthritis (PsA) often suffer from anxiety disorders. While upadacitinib has shown effectiveness in reducing various disease activity indicators in active PsA, its impact on anxiety disorders in PsA patients
Externí odkaz:
https://doaj.org/article/2247bf0fd237477f9aef3eef87cb9237
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis
Autor:
Andrew Blauvelt, Kilian Eyerich, Alan D. Irvine, Marjolein de Bruin-Weller, Shawn G. Kwatra, Melinda Gooderham, Brian Kim, Brian M. Calimlim, Wan-Ju Lee, Eliza M. Raymundo, Yingyi Liu, Sarah Ofori, Andrew M. Platt, Jonathan I. Silverberg
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2621-2630 (2024)
Abstract Introduction Atopic dermatitis (AD), with its hallmark symptoms of pruritus and skin lesions, often impairs patients’ quality of life. We assessed time spent with clear/almost clear skin and no/minimal itch during upadacitinib treatment ve
Externí odkaz:
https://doaj.org/article/f20cd55b09a34e87a0a91cfbd7f735cf
Autor:
April W. Armstrong, H. Chih-Ho Hong, Brian M. Calimlim, Marric G. Buessing, Marjorie M. Crowell, Jonathan I. Silverberg
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2457-2465 (2024)
Abstract Introduction Efficacy of upadacitinib has been assessed in trials including Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and Heads Up (NCT03738397). Measure Up 1 and 2 assessed efficacy of upadacitinib 30 mg and upadacitinib 15 mg
Externí odkaz:
https://doaj.org/article/c50f79e2bc6f4b5e8459d5588f42735c
Autor:
Ronald van Vollenhoven, Vibeke Strand, Tsutomu Takeuchi, Nilmo Chávez, Pablo Mannucci Walter, Atul Singhal, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, Sara K. Penn, Heidi S. Camp, Jacob Aelion
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-15 (2024)
Abstract Background To evaluate the efficacy and safety of upadacitinib monotherapy versus methotrexate (MTX) monotherapy over 5 years among MTX-naïve patients with moderately to severely active rheumatoid arthritis (RA) in the long-term extension (
Externí odkaz:
https://doaj.org/article/d96238b03a104e99a640cf8bd22d5e92
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 4, Pp 1298-1300 (2024)
Externí odkaz:
https://doaj.org/article/770611cda130447d98b1053c117a54bb
Autor:
Javier Loricera, Toluwalase Tofade, Diana Prieto-Peña, Susana Romero-Yuste, Eugenio de Miguel, Anne Riveros-Frutos, Iván Ferraz-Amaro, Eztizen Labrador, Olga Maiz, Elena Becerra, Javier Narváez, Eva Galíndez-Agirregoikoa, Ismael González-Fernández, Ana Urruticoechea-Arana, Ángel Ramos-Calvo, Fernando López-Gutiérrez, Santos Castañeda, Sebastian Unizony, Ricardo Blanco
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background A substantial proportion of patients with giant cell arteritis (GCA) relapse despite standard therapy with glucocorticoids, methotrexate and tocilizumab. The Janus kinase/signal transducer and activator of transcription (JAK/STAT)
Externí odkaz:
https://doaj.org/article/d674a733557b4bc69d8a92f5cf68aa95
Autor:
Shahed Kamal, Sheng Wei Lo, Samantha McCall, Beverly Rodrigues, Andrew H. Tsoi, Jonathan P. Segal
Publikováno v:
Biologics, Vol 4, Iss 2, Pp 177-186 (2024)
Background: Janus kinase (JAK) inhibitors represent a novel class of oral therapies showing efficacy in treating ulcerative colitis (UC) and Crohn’s disease (CD), challenging conventional treatment paradigms. Summary: This review provides an overvi
Externí odkaz:
https://doaj.org/article/1716a5aa3a404f73bc4f5652574fdebb
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1389-1442 (2024)
Abstract Introduction Biological drugs (BD) and Janus kinase inhibitors (JAKi) have revolutionized the treatment of diverse dermatoses. However, there are concerns regarding their safety, especially the risk of cancer and opportunistic infections. He
Externí odkaz:
https://doaj.org/article/410903b1deb64e15bee541171f19a160
Autor:
Eric L. Simpson, Vimal H. Prajapati, Yael A. Leshem, Raj Chovatiya, Marjolein S. de Bruin-Weller, Sonja Ständer, Andrew E. Pink, Brian M. Calimlim, Wan-Ju Lee, Henrique Teixeira, Barry Ladizinski, Xiaofei Hu, Yang Yang, Yingyi Liu, Meng Liu, Ayman Grada, Andrew M. Platt, Jonathan I. Silverberg
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 5, Pp 1127-1144 (2024)
Abstract Introduction Atopic dermatitis (AD) is characterized by intense itch and other symptoms that negatively impact quality of life (QoL). This study evaluates the effect of upadacitinib (an oral selective Janus kinase inhibitor) monotherapy on p
Externí odkaz:
https://doaj.org/article/d13086b1bc984adeabc8518d220ee7d9
Autor:
Kevin M. Burningham, MD, Kritin K. Verma, BS, MBA, Anisha B. Patel, MD, Stephen K. Tyring, MD, PhD, MBA
Publikováno v:
JAAD Case Reports, Vol 46, Iss , Pp 81-84 (2024)
Externí odkaz:
https://doaj.org/article/1898a0a4ee704e898f5528663854e028